Date Article
------------ ----------------------------------------
UCB Announces PDUFA Date for Bimekizumab
Is bimekizumab approved?
Bimekizumab is the first approved psoriasis treatment in Japan that is designed to selectively and directly inhibit two key cytokines driving inflammatory processes interleukin 17F (IL-17F) and interleukin 17A (IL-17A).
What is the brand name for ustekinumab?
Monoclonal antibody
-------------------
Target
Clinical data
Trade names
Other names
Is bimekizumab a biologic?
Bimekizumab is a new biologic that inhibits both IL-17AIL-17AStructure. IL-17(A) is a 155-amino acid protein that is a disulfide-linked, homodimeric, secreted glycoprotein with a molecular mass of 35 kDa.https://en.wikipedia.org › wiki › Interleukin_17Interleukin 17 - Wikipedia and IL-17F. It is currently in phase III clinical trials.
Is bimekizumab approved by FDA?
Date Article
------------ --------------------------------------------------------------------------------
Update on U.S. FDA Review of Biologics License Application (BLA) for Bimekizumab
What is the brand name for bimekizumab?
Monoclonal antibody
-------------------
Trade names
License data
ATC code
Legal status
When will bimekizumab be available?
If approved, UCB will release bimekizumab to patients starting in the second half of 2021.
What is bimekizumab used for?
Bimekizumab was highly effective for treating patients with moderate to severe plaque psoriasis in 2 phase 3 trials published in The Lancet. Bimekizumab is a novel, subcutaneously injected monoclonal IgG1 antibody that selectively inhibits interleukin 17F (IL-17F) in addition to IL-17A.
How effective is Stelara for psoriasis?
Effectiveness for plaque psoriasis In clinical studies, Stelara was effective in treating adults and adolescents with moderate to severe plaque psoriasis. After 12 weeks of treatment: Up to 73% of adults taking Stelara had very few plaques to no plaques on their skin.
Is Cosentyx considered a biologic?
COSENTYX is a biologic that helps reduce the symptoms of ankylosing spondylitis (AS), like back pain and morning stiffness. It's the first biologic of its kind to treat AS by targeting a molecule called IL-17A.
How bimekizumab works?
Bimekizumab is a humanized IgG1 monoclonal antibody that simultaneously and selectively inhibits the biological functions of both IL-17A and IL-17F.Jun 8, 2021